Parasitic (Helminthic) Infection While on Asthma Biologic Treatment: Not Everything Is What It Seems.
Laren D TanBrett SchaefferAbdullah AlismailPublished in: Journal of asthma and allergy (2019)
Asthma is a chronic inflammatory disorder of the airway that is characterized by bronchial hyperresponsiveness and variable airflow limitation. Approximately 235 million people are affected by asthma worldwide and 5-10% are considered to be refractory to standard asthma treatment. These patients are known to have repeated exacerbations requiring multiple courses of systemic corticosteroids and as a result, are at risk for increased adverse effects (i.e., osteoporosis, infections). Several new medications known as biologic agents have been approved for the treatment of moderate-to-severe asthmatics. These biologic agents target essential parts of the cell-mediated allergic and to a lesser degree non-allergic immune response (IgE, IL-5, and IL-4/IL-13). They are gaining more favor in the treatment of moderate-to-severe asthma due to their efficacy and excellent safety profile. Despite the most common adverse events being minor, such as injection site reactions, upper respiratory infections, or headaches, these agents carry a small risk of more severe complications such as anaphylaxis and decreased defense against parasitic infections (PI). The incidence of PI compared with other rare adverse events is not well reported, and there are no consensus guidelines for risk prevention of PI in asthmatics undergoing evaluation for, or currently using, biologic therapy. Thus, this article sets out to review the incidence of reported PI and other rare adverse events among asthmatics using current FDA-approved biologic therapies. Secondly, we discuss the clinical implications for the importance of risk prevention of PI with the use of biologic therapies in asthmatics. Lastly, we share an educational handout to assist providers in informing their patients of behaviors that could potentially increase their risk of PI while being on a biologic agent.
Keyphrases
- rheumatoid arthritis
- chronic obstructive pulmonary disease
- immune response
- end stage renal disease
- lung function
- ejection fraction
- stem cells
- chronic kidney disease
- risk factors
- newly diagnosed
- allergic rhinitis
- mesenchymal stem cells
- cystic fibrosis
- oxidative stress
- early onset
- cell therapy
- bone mineral density
- ultrasound guided
- air pollution
- patient reported outcomes
- toll like receptor
- smoking cessation
- respiratory tract